Association of interleukin 18-607A/C and -137C/G polymorphisms with oxidative stress in renal transplant recipients

Figures & data

Table 1. Demographic features of all patients and IL18–607/–137 gene polymorphism groups.

	All patients	IL18-607 gene polymorphism			IL18-137 gene polymorphism
		Wild (CC)	Mutant (AA)	Heterozygote (CA)	Wild (GG)	Mutant (CC)	Heterozygote (GC)
Numbers (%)	75 (100)	40 (53)	13 (17)	22 (30)	49 (65)	2 (3)	24 (32)
Recipient age (year)	38.2 ± 13	38.1 ± 14.2	40 ± 14.2	37.5 ± 10.1	36.3 ± 12.6	33.5 ± 0.7	42.5 ± 13.6
Donor age (year)	47.2 ± 12.2	47.4 ± 12.4	45.9 ± 10.8	47.8 ± 13.1	47.9 ± 11.8	53.5 ± 4.9	45.4 ± 13.5
Gender (F/M) (%)	28/47 (36/64)	14/26 (35/65)	7/6 (53/47)	7/15 (32/68)	18/31 (37/63)	1/1 (50/50)	9/15 (37/63)
BMI (kg/m^2)	24.1 ± 4.9	25 ± 4.8	22.3 ± 3.2	23.6 ± 5.3	23.8 ± 5	20 ± 0.5	25.1 ± 4.4
Types of renal replacement therapy
PD	5 (7%)	5 (13%)	0	0	5 (10%)	0	0
HD	31 (41%)	16 (40%)	5 (38%)	10 (45%)	21 (43%)	0	10 (41%)
Preemptive	39 (52%)	19 (47%)	8 (62%)	12 (55%)	23 (47%)	2 (100%)	14 (59%)
The etiologies of end stage renal disease
Hypertension	18 (24%)	8 (20%)	4 (31%)	6 (27%)	8 (16%)	0	10 (42%)
DM	8 (11%)	5 (13%)	1 (8%)	2 (9%)	6 (13%)	1 (50%)	1 (4)
Nephrolithiasis	11 (15%)	5 (13%)	2 (15%)	4 (18%)	8 (16%)	0	3 (13%)
GN	6 (8%)	1 (4%)	2 (15%)	3 (14%)	4 (8%)	0	2 (8%)
Unknown	25 (32%)	16 (40%)	4 (31%)	5 (23%)	18 (37%)	1 (50%)	6 (25%)
Other	7 (10%)	5 (10%)	0	2 (9%)	5 (10%)	0	2 (8%)
The number of HLA matches
0	9 (12%)	6 (16%)	1 (8%)	2 (9%)	7 (14%)	0	2 (8%)
1–5	60 (80%)	31 (76%)	11 (84%)	18 (82%)	38 (78%)	2 (100%)	20 (84%)
6	6 (8%)	3 (8%)	1 (8%)	2 (9%)	4 (8%)	0	2 (8%)

PD, peritoneal dialysis; HD, hemodialysis; DM, diabetes mellitus; GN, glomerulonephritis. Results are expressed as numbers and percentages.

Table 2. Frequency of alleles and genotypes of interleukin-18 gene promoter polymorphism in kidney recipients.

	Parameters	n	%
IL-18-607	C Allele frequency	102	68
	A Allele frequency	48	32
	CC Genotype frequency	40	53
	CA Genotype frequency	22	30
	AA Genotype frequency	13	17
IL-18-137	G Allele frequency	122	81
	C Allele frequency	28	19
	GG Genotype frequency	49	65
	GC Genotype frequency	24	32
	CC Genotype frequency	2	3

Figure 1. The oxidative stress parameters before and after transplantation at day 7 and month 1. Data are given as mean ± standard error.

Table 3. Serum creatinine, cystatin-C, CRP, IL-18, TAC, TOS levels, OSI, and eGFR values before and after transplantation at day 7 and month 1. Data are given as mean ± standard error.

Parameters	Pre-transplant^a	Post-transplant day 7^b	Post-transplant month 1^c	p Values
Creatinine (mg/dL)	8.18 ± 2.83	1.30 ± 0.39	1.32 ± 0.41	1–2 = 0.001
				1–3 = 0.001
				2–3 = 0.355
GFR-CKD-EPI (mL/dk/1.73m^2)	7.77 ± 3.02	69.03 ± 21.98	68.80 ± 24.00	1–2 = 0.001
				1–3 = 0.001
				2–3 = 0.759
Cystatin-C (mg/L)	5.18 ± 1.51	1.60 ± 0.43	1.58 ± 0.27	1–2 = 0.001
				1–3 = 0.001
				2–3 = 0.558
CRP (mg/L)	0.43 ± 0.20	0.54 ± 0.23	0.13 ± 0.09	1–2 = NS
				1–3 = 0.001
				2–3 = 0.001
IL-18 (pg/mL)	228.46 ± 110.70	197.65 ± 85.53	202.51 ± 86.78	1–2 = 0.001
				1–3 = 0.026
				2–3 = 0.233
TAC (Trolox Equiv mmol/L)	0.43 ± 0.09	0.45 ± 0.06	0.46 ± 0.05	1–2 = 0.006
				1–3 = 0.006
				2–3 = 0.639
TOS (μmol H2O2 Equiv/L)	37.21 ± 31.64	12.40 ± 10.71	11.48 ± 6.85	1–2 = 0.001
				1–3 = 0.001
				2–3 = 0.132
OSI (AU)	5.72 ± 1.77	2.48 ± 1.40	2.36 ± 1.10	1–2 = 0.001
				1–3 = 0.001
				2–3 = 0.621

p Values of different periods are given in Table 2. p < 0.05 was accepted as significant and signed as bold. NS, not significant.

a Pre-transplant.

b Post-transplant day 7.

c Post-transplant month 1.